An Open-Label, Randomized, Phase 3 Clinical Trial of the checkpoint inhibitor REGN2810 versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or metastatic Platinum-Refractory Cervical Carcinoma
Sponsor: Regeneron Pharmaceuticals, Inc
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Leuven, Leuven
- Clinique CHC Montlégia, Liège
- Institut Jules Bordet, Bruxelles
- CHU UCL St. Luc, Bruxelles
- OLV Aalst, Aalst
- CHU de Liège, site Sart Tilman, Liège
